'Raloxifene' diaporamas de présentation

Evidence-Based Management of Osteoporosis

Evidence-Based Management of Osteoporosis. A Systematic Review of Agents Currently Available for Osteoporosis and their Use in Clinical Practice. Benefits of Therapy: Summary. Contemporary pharmacologic treatments significantly decrease fracture risk:

1.31k views • 76 slides

Med/Surg I, Module 4 Part 1 of 4

Med/Surg I, Module 4 Part 1 of 4. Orthopedic System Alteration in Mobility Integumentary System. Chronic Musculoskeletal Conditions. Curvature of the Spine Osteoporosis Osteomyelitis Osteoarthritis. Curvature of the Spine. Kyphosis (left) and Lordosis (right). Kyphosis

1.12k views • 76 slides

806 views • 55 slides

661 views • 53 slides

Osteoarthritis and Osteoporosis

Osteoarthritis and Osteoporosis. Rochelle M. Nolte, MD CDR USPHS. Objectives. Participants will be able to: Discuss the epidemiology of osteoarthritis and osteoporosis in the geriatric population List 3 risk factors for osteoarthritis and osteoporosis in the geriatric population

2.12k views • 51 slides

Osteoporosis

Osteoporosis. Stephanie Wetmore, PT PED 596: Adv. Cardiac Rehab Wayne State College. Osteoporosis. A disease characterized by irregularities in the quantity and architectural arrangement of bone tissue that lead to decreased skeletal strength and increased vulnerability to fractures .

576 views • 46 slides

Hormone Replacement Therapy and Alternatives after WHI

680 views • 44 slides

Monica Morrow MD Chief, Breast Surgery Service Anne Burnett Windfohr Chair of Clinical Oncology Memorial Sloan-Kettering

18 th Annual Perspectives in Breast Cancer New York, NY. Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065. 18 August 2012. Treatment Decision Making for DCIS. Monica Morrow MD Chief, Breast Surgery Service Anne Burnett Windfohr Chair of Clinical Oncology

680 views • 37 slides

Question

Approaches to Mitigating the Bioactivation Potential of Compounds in Lead Optimization Deepak Dalvie Pharmacokinetics, Dynamics and Metabolism Department Pfizer San Diego. Question. Is covalent binding or GSH Adduct Formation a kill shot for a candidate??.

674 views • 36 slides

Menopause and Hormone Therapy

1k views • 30 slides

An Industry Guide to Partnering with the National Cancer Institute, NIH

An Industry Guide to Partnering with the National Cancer Institute, NIH. Tom Stackhouse, Ph.D. Technology Transfer Branch National Cancer Institute National Institutes of Health. December 09, 2003.

379 views • 27 slides

Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women

Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women. Implementing NICE guidance. 2008. NICE technology appraisal guidance 160 and 161. What this presentation covers. Definitions and scope Background Recommendations Costs and savings Discussion

349 views • 21 slides

Pharmacologic agents to prevent and treat osteoporosis

407 views • 20 slides

Cancer Prevention: Clinical Trials

Cancer Prevention: Clinical Trials. Christina Laukaitis, MD, PhD, FACP 22 June 2012.

358 views • 20 slides

Menopause

491 views • 20 slides

FDA Presentation ODAC Meeting July 24 2007

313 views • 16 slides

Osteoporosis: The era of the bisphosphonates Part 1 PowerPoint Slides

472 views • 15 slides

Osteoporosis: The era of the bisphosphonates Part 2 PowerPoint Slides

Osteoporosis: The era of the bisphosphonates Part 2 PowerPoint Slides. -2.5. -2. 1. 0. World Health Organization (WHO) guidelines for osteoporosis. Peak Bone Mass. Normal. Osteoporosis. Osteopenia. T-Score. Current treatment options for osteoporosis. Treatment Dosage Form

568 views • 14 slides

Effects of Osteoporosis Treatments

476 views • 7 slides